Rapid eGFR Decline Management

Introduction to eGFR Decline

The American College of Physicians recommends immediate nephrology referral for patients with a rapid decline in eGFR, defined as a decline of >5 mL/min/1.73 m²/year, due to the high risk of adverse outcomes 1, 3
A >50% decline in eGFR is associated with a significantly increased risk of end-stage kidney disease, with a 20-fold increased risk compared to stable eGFR 3

The National Kidney Foundation recommends repeating serum creatinine and eGFR within 48-72 hours to confirm the decline and rule out acute kidney injury 3
The American Journal of Kidney Diseases suggests calculating the rate of decline, with an annual decline of >5 mL/min/1.73 m²/year indicating rapid progression 3
Obtain a spot urine albumin-to-creatinine ratio (UACR) to assess for albuminuria, which is essential for risk stratification and determining the etiology of kidney disease 1, 5
UACR ≥300 mg/g in the setting of diabetes and a significant eGFR decline strongly suggests diabetic kidney disease 1, 6

The Mayo Clinic recommends immediately discontinuing nephrotoxic medications, such as NSAIDs, aminoglycosides, and calcineurin inhibitors, to prevent further kidney damage 2, 7
Review recent contrast exposure, as radiocontrast is particularly nephrotoxic in diabetic nephropathy 8
Assess for volume depletion, heart failure, or cirrhosis, which can cause reduced renal perfusion 2, 4, 9

The American Journal of Kidney Diseases recommends screening for CKD complications, including hyperkalemia, metabolic acidosis, anemia, and mineral bone disease, in patients with an eGFR <45 mL/min/1.73 m² 1, 2, 5, 7
Perform a complete metabolic panel, complete blood count, and serum calcium, phosphate, intact PTH, and 25-hydroxyvitamin D to assess for CKD complications 2, 5, 7

The American College of Cardiology recommends initiating or maximizing ACE inhibitor or ARB therapy, particularly if UACR ≥30 mg/g, to slow CKD progression and reduce cardiovascular risk 1, 2, 8
Consider adding an SGLT2 inhibitor, such as empagliflozin or dapagliflozin, if eGFR remains ≥20 mL/min/1.73 m², as these reduce CKD progression and cardiovascular events 9, 1, 2
Initiate high-intensity statin therapy for cardiovascular risk reduction, as CKD patients have a 5-10 times higher cardiovascular mortality risk 2, 7, 4

The National Kidney Foundation recommends monitoring eGFR, UACR, and serum potassium every 1-2 months until stabilized, with more frequent monitoring warranted in patients with rapid eGFR decline 1, 2
Monitor UACR 3-4 times per year if ≥300 mg/g, and 2-3 times per year if 30-300 mg/g 1

The American Heart Association recommends restricting protein intake to 0.8 g/kg/day to slow CKD progression, and restricting sodium to <2.0 g/day to enhance blood pressure control and reduce proteinuria 8, 7, 4
Avoid protein intake <0.6 g/kg/day due to malnutrition risk 7

Do not delay nephrology referral, as earlier involvement improves outcomes and preparation for renal replacement therapy 7
Do not discontinue ACE inhibitors or ARBs for creatinine increases <30% in the absence of volume depletion or hyperkalemia 2, 7
Do not rely on serum creatinine alone, and always calculate eGFR using validated equations (CKD-EPI 2021) 2
Do not skip albuminuria testing, as eGFR and UACR provide independent prognostic information for cardiovascular events, CKD progression, and mortality 2, 4